Amylin/Lilly's Byetta approved in Europe for use with basal insulin
This article was originally published in Scrip
Executive Summary
The European Commission has granted marketing authorisation to Amylin Pharmaceuticals and Lilly's Byetta (exenatide twice daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycaemic control with these agents.